A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

• Status: Completed
• Trial end date: 1969-12-31

Summary

The primary objective of this trial is to explore the overall objective best response rate and the rate of non-progression at 16 weeks of sequential, alternating weekly administration of BIBF 1120 and BIBW 2992 in patients with metastatic CRC based on the RECIST criteria.

• Phase: Phase 2

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Afatinib; Nintedanib